PROSEEK study shows no treatment benefit of Vodobatinib in patients with early Parkinson’s Disease EP News Bureau Apr 10, 2024 Both low dose and high dose Vodobatinib arms did not meet the pre-specified primary endpoint of change in MDS-UPDRS Part III total…
